A Phase 1 Dose Escalation Study of ARQ 751 in Adult Subjects With Advanced Solid Tumors With AKT1, 2, 3 Genetic Alterations, Activating PI3K Mutations, PTEN-null, or Other Known Actionable PTEN Mutations

Trial Profile

A Phase 1 Dose Escalation Study of ARQ 751 in Adult Subjects With Advanced Solid Tumors With AKT1, 2, 3 Genetic Alterations, Activating PI3K Mutations, PTEN-null, or Other Known Actionable PTEN Mutations

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Mar 2018

At a glance

  • Drugs ARQ 751 (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Sponsors ArQule
  • Most Recent Events

    • 05 Mar 2018 According to an ArQule media release, data anticipated in 2018.
    • 19 Feb 2018 Planned End Date changed from 1 Mar 2018 to 1 Mar 2019.
    • 19 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top